The ATP analog, kinetin triphosphate which pharmacologically activates PINK1, restores the kinase activity of a PD-associated mutant of PINK1 and concomitantly elevating the kinase activity of endogenous wild-type PINK1, uncovering a potential new approach for therapeutically targeting the PINK1/Parkin pathway [60]. This evidence concerns the gene PRKN and Parkinson disease.